Vir Biotechnology (VIR) Fundamental Analysis: Revenue, Earnings & Valuation

2.94 / 10

Underperform

Fundamental analysis rates VIR as Underperform (2.9/10). Revenue‑MV and Cash‑MV show relative strength, but Asset‑MV and Fixed‑Asset turnover are weak. Key factor scores: PB‑ROE –0.24 (group2), Asset‑MV –0.55 (group4), Revenue‑MV –0.64 (group1). Overall fundamentals appear inadequate.

Analysis Checks(7/10)

Revenue-MV

Value-0.64

Score2/3

Weight19.09%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-7.61

Score2/3

Weight-1.88%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight15.56%

1M Return6.74%

Gross profit margin (%)

Value99.96

Score2/3

Weight3.55%

1M Return1.69%

PB-ROE

Value-0.24

Score1/3

Weight13.04%

1M Return5.29%

Income tax / Total profit (%)

Value-0.05

Score2/3

Weight2.08%

1M Return1.04%

Fixed assets turnover ratio

Value0.57

Score1/3

Weight-2.17%

1M Return-1.24%

Cost of sales ratio (%)

Value0.04

Score3/3

Weight9.00%

1M Return4.32%

Asset-MV

Value-0.55

Score1/3

Weight27.91%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight13.82%

1M Return5.94%

Is VIR undervalued or overvalued?

VIR scores 2.94/10 on fundamentals and holds a Premium valuation at present. Backed by its -45.73% ROE, -638.87% net margin, -3.04 P/E ratio, 1.74 P/B ratio, and 17.49% earnings growth, these metrics solidify its Underperform investment rating.